McKenzie Prillaman is a reporter with The Cancer Letter. She joined the publication in 2024.
Before joining The Cancer Letter, McKenzie was a freelance science and health journalist writing for Nature, Science News, APS News and AARP, among other publications. She earned a master’s degree in science communication from the University of California, Santa Cruz in 2022.
McKenzie previously worked at the Dialogue on Science, Ethics and Religion program of the American Association for the Advancement of Science, and studied adolescent nicotine dependence at the National Institute on Drug Abuse. She graduated from the University of Virginia in 2017 with a bachelor’s degree in neuroscience and a minor in bioethics.
Before joining The Cancer Letter, McKenzie was a freelance science and health journalist writing for Nature, Science News, APS News and AARP, among other publications. She earned a master’s degree in science communication from the University of California, Santa Cruz in 2022.
McKenzie previously worked at the Dialogue on Science, Ethics and Religion program of the American Association for the Advancement of Science, and studied adolescent nicotine dependence at the National Institute on Drug Abuse. She graduated from the University of Virginia in 2017 with a bachelor’s degree in neuroscience and a minor in bioethics.
Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report.
Mace Rothenberg has stayed busy since stepping down as Pfizer’s chief medical officer in 2021 by pivoting to an ambitious endeavor in science communication: the Museum of Medicine and Biomedical Discovery.
Clinical
A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?
Free
Something odd turned up in one of Lawrence Phillips’s routine health screenings in 2008.
White House
What will happen to biomedical research and health care in the aftermath of the 2024 election? The differences in outcomes couldn’t be more stark.
White House
Source: Livestream of White House Africa Cancer Care ForumThe White House Cancer Moonshot is committing an additional $100 million to programs focused on reducing cancer burden in African countries.
